[Treatment of mild and moderate hypertension with enalapril (multicenter study of enap and enap N in Ukraine)].
OBJECTIVE
Assessment of efficiency and safety of enalapril (enap) and its combination with hydrochlorotiaside (enap-N).


METHODS
127 patients with mild and moderate blood hypertension entered an open non-comparative multicenter trial. 60 of them received enap (group 1), 67--enap N (group 2). Group 1 patients were given enap for 2 weeks in a dose 10 mg/day. If this dose was not adequate to normalize blood pressure, it was raised to 20-40 mg/day. Patients of group 2 received enap-N one tablet a day for 3 weeks. If the pressure persisted higher than 140/90 mm Hg, the treatment was continued for 3 weeks more in a dose of 2 tablets a day.


RESULTS
Blood pressure lowered under 140/90 mm Hg in 40 patients of group 1 (66.7%). Systolic pressure dropped by 10 mm Hg minimum and diastolic by 5 mm minimum in 18 group 1 patients (30%). Enap-N reduced blood pressure under 140-90 mm Hg in 44 of 67 patients (65.7%). Systolic and diastolic pressure dropped, respectively, in 23(34.3%) patients.


CONCLUSIONS
Enap and enap-N tablets were found highly effective and well tolerated. Side effects were caused by lowering of blood pressure.
Dziak
G V
GV
Kolomiets
S N
SN
Minakov
A I
AI
Fushteĭ
I M
IM
Iavorskiĭ
O G
OG
Bekker
V F
VF
Vankhanen
V N
VN
Davydova
I V
IV
Zaĭtseva
V I
VI
Kolesnik
T V
TV
Kolomiets
V V
VV
Svishchenko
E P
EP
Taran
A I
AI
Shlykova
N A
NA
Barbich-Zhagar
B
B
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D012449:Safety; D012720:Severity of Illness Index; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D004656:Enalapril